Endocrine & reproductive

What actually decides this outcome, in order of size

Something is different about this page compared with every other bioregulator pathway, and it is the reason to read it carefully: every claim made here has a blood test attached to it. Ranked by how much of the outcome each one owns:

1. That these claims are falsifiable, and have not been falsified. A testicular peptide proposing Leydig support predicts a measurable change in testosterone and gonadotropins. An ovarian one predicts a change in a follicular marker. A pancreatic one predicts a change in glycemic handling. A prostate one predicts a change in a prostate-specific antigen and a symptom score. Every one of those numbers is orderable today. Nobody outside the originating program has run any of those comparisons.
2. Where the closest supporting result comes from, and it is a primate study. The tetrapeptide pancragen was examined for its impact on endocrine function in aging animals Goncharova 2014. That is the nearest thing on this page to an endocrine endpoint measured in a living organism, and it is not a human trial.
3. What the mechanism claim actually is, because it is a transcriptional one. Peptide regulation of gene expression has a systematic review from within the program Khavinson 2021, structural motifs for peptide-DNA binding have been searched for systematically Kolchina 2019, and transport of ultrashort peptides through amino acid transporters has been modeled Khavinson 2023. A cell-level effect on the monocyte line has been reported with international co-authorship Avolio 2022, which is the broadest authorship any of this work has.
4. Whether the reader is treating an axis that is already measurably abnormal, or one they assume is. A low testosterone needs a repeated morning sample and a gonadotropin pair before anything is concluded Bhasin 2018. Buying a testicular peptide without that pair is the same mistake the whole testosterone-booster category makes, and that category has been systematically reviewed and found largely unsupported Morgado 2023.
5. The peptides, last, and the only human outcome ever claimed for the series is survival. Pineal and thymic peptide preparations were reported to prolong human life in a long-running follow-up Khavinson 2003, with earlier animal work on vilon Khavinson 2000. That is the largest claim on this site and it rests on a body of work that an outside review of the broader class treats cautiously Alsulaimani 2021.

The order to run these in, and what has to be true first

Measure the axis before signaling to it. This page is the one place on the site where a reader can run the experiment the literature has not run, and doing it in the wrong order wastes the only informative thing about the purchase.

1. Decide which axis you are buying for, and take its baseline first. One requisition per axis, morning, and a repeat draw on a separate day for anything that is going to drive a decision Bhasin 2018. Without a baseline there is no experiment, only a subscription.
2. Testoluten and Testagen predict a change in LH & FSH and Total Testosterone with SHBG (Sex Hormone-Binding Globulin). If the proposal is Leydig-cell support, the honest signature is testosterone rising while luteinizing hormone stays flat or falls, because a gonadal effect relieves the feedback. Testosterone rising with LH rising means something acted above the testis, which is a different claim from the one on the label.
3. Ovagen predicts a change in Anti-Müllerian Hormone (AMH) with Progesterone timed to the luteal phase. Anti-Mullerian hormone reflects the antral follicle pool and is comparatively stable across the cycle, which makes it the one follicular marker a before-and-after comparison can use. There is no independent human data for this peptide on that endpoint or any other.
4. Prostamax predicts a change in PSA (Total + Free + % Free) and in a symptom score, and the first of those has a safety meaning. Prostate-specific antigen is not only an efficacy read-out on this page; it is the number that must not be allowed to drift upward unexamined while somebody attributes their symptoms to a peptide. This is the single most important instruction on the page.
5. Suprefort and Pancragen predict a change in Fasting Insulin, C-Peptide, Serum and HbA1c (Hemoglobin A1c). The animal endocrine work is the pancreatic one Goncharova 2014, and C-peptide is the analyte that separates endogenous insulin output from exogenous insulin. If a pancreatic peptide does anything, this is where it would show, and a 12-week HbA1c is the window.
6. Endoluten is positioned as the master endocrine peptide and is the hardest to test. Melatonin is not on this site's marker list and the pineal claim has no ordinary assay, so the falsifiable proxies are IGF-1 (Insulin-like Growth Factor 1) and Prolactin, both of which are sleep-linked. That makes the honest version of this peptide's claim a circadian one, and it routes to Circadian & melatonergic rhythm for anybody whose actual complaint is sleep timing.
7. Do not run two of these at once. Each targets a different axis with a different read-out and a different window, and running a testicular and a pancreatic peptide in the same 12 weeks makes both results uninterpretable. The whole value of this page is that it is testable.

What gets bought for this that cannot move it

The category fails on independent replication, and on this page it fails harder than on the organ page next door, because here the test exists. The evidence base is a single research program Khavinson 2021 Kolchina 2019 with an outside review of the broader class that is not enthusiastic Alsulaimani 2021. When a claim can be checked with a routine assay and has not been checked in thirty years, that absence is itself information.

Prostamax is the item here with a real potential for harm, and the harm is delay. A man attributing urinary symptoms to a peptide and not tracking PSA (Total + Free + % Free) is doing the one thing this page must tell him not to do. The peptide has no independent human evidence; the antigen has decades of it. Whatever else happens, the number gets watched.

The oral preparations are the half of this shelf whose equivalence claim is weakest. The transport argument is structural and computational Khavinson 2023, and the reported cellular effects are in culture Avolio 2022. Neither establishes that an orally administered tri- or tetrapeptide reaches an endocrine gland in a person at a concentration that does anything.

And if the axis is genuinely abnormal, this is the wrong page. A low testosterone with a low or normal LH belongs at Upstream stimulation — keeping the axis running, which has drugs with trials. Irregular cycles and androgen excess belong at PCOS — insulin, androgens & ovulation. A raised HbA1c belongs at AMPK activation & cellular fuel sensing and Glucose disposal, absorption & the post-meal curve. A rising PSA belongs with a urologist the same month.

How you would know it was working, on a real read-out and a real timescale

This page's prediction is the sharpest in the cohort because every claim on it is numeric. If a testicular peptide works as described, Total Testosterone rises while LH & FSH does not. If a pancreatic one works, C-Peptide, Serum and HbA1c (Hemoglobin A1c) move together. If nothing moves in 12 weeks on a correctly-timed pair of draws, the peptide did not do the thing it is sold to do, in you.

• Total Testosterone with LH & FSH and SHBG (Sex Hormone-Binding Globulin), morning and fasted, at baseline and 8 weeks. Eight weeks because a gonadal effect has to work through Leydig steroidogenesis and then through pituitary feedback, and because a shorter window cannot separate a real change from the diurnal and day-to-day variability of the hormone Bhasin 2018.
• Anti-Müllerian Hormone (AMH) at baseline and 3 months for the ovarian claim. Anti-Mullerian hormone reflects a follicle pool that turns over slowly, so a 3-month interval is the shortest one in which a change would mean anything, and a change inside the assay's own variability means nothing.
• PSA (Total + Free + % Free) at baseline and 3 months for the prostate claim, and then regardless of the peptide. The interval is set by the antigen's half-life and by the fact that transient elevations from prostatitis, cycling and ejaculation settle over weeks. This is a safety read-out first and an efficacy read-out second.
• Fasting Insulin with C-Peptide, Serum and HbA1c (Hemoglobin A1c) at baseline and 12 weeks for the pancreatic claim. C-peptide is co-secreted with insulin at one to one and is cleared more slowly, which makes it the better index of endogenous beta-cell output; the animal endocrine work is the closest supporting evidence Goncharova 2014.
• IGF-1 (Insulin-like Growth Factor 1) with Prolactin at baseline and 12 weeks for the pineal claim. Both are sleep-linked and both are orderable, which makes them the only falsifiable proxies available for a peptide whose stated target has no routine assay.

What will fool you. Testosterone falls with a bad week and rises with a good one, so a single pair of draws around a stressful period will show whatever the period did. AMH differs between assay platforms enough that a laboratory change invalidates the comparison. PSA rises transiently after cycling, ejaculation or a urinary infection, so a raised value is repeated before it is acted on. And the strongest claim attached to this series is a survival claim from within the program itself Khavinson 2003, which is precisely the kind of endpoint no reader can verify on themselves in any timeframe Alsulaimani 2021.

Sources read for these sections

• Goncharova ND, Ivanova LG, Oganian TÉ, Vengerin AA, Khavinson VKh. Impact of tetrapeptide pancragen on endocrine function of the pancreas in old monkeys. Advances in Gerontology 2014;27(4):662–667 · PMID 25946840
• Khavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide Regulation of Gene Expression: A Systematic Review. Molecules 2021;26(22):7053 · PMID 34834147
• Kolchina N, Khavinson V, Linkova N, Yakimov A, Baitin D, Afanasyeva A, Petukhov M. Systematic search for structural motifs of peptide binding to double-stranded DNA. Nucleic Acids Research 2019;47(20):10553–10563 · PMID 31598715
• Khavinson VK, Linkova NS, Rudskoy AI, Petukhov MG. Feasibility of Transport of 26 Biologically Active Ultrashort Peptides via LAT and PEPT Family Transporters. Biomolecules 2023;13(3):552 · PMID 36979488
• Alsulaimani RA, Quinn TJ (independent — not the Khavinson group). The efficacy and safety of animal-derived nootropics in cognitive disorders: Systematic review and meta-analysis. Cerebral Circulation – Cognition and Behavior 2021;2:100012 · PMID 36324709
• Khavinson VKh, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinology Letters 2003;24(3-4):233–240 · PMID 14523363
• Avolio F, et al. (co-authors include Khavinson VKh). Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line. International Journal of Molecular Sciences 2022;23(7):3607 · PMID 35408963
• Khavinson VK, Anisimov VN, Zavarzina NY, Zabezhinskii MA, Zimina OA, Popovich IG, Shtylik AV, Malinin VV, Morozov VG. Effect of vilon on biological age and lifespan in mice. Bulletin of Experimental Biology and Medicine 2000;130(1):687–690
• Bhasin S. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism 2018;103(5):1715-1744 · PMID 29562364
• Morgado A. Do “testosterone boosters” really increase serum total testosterone? A systematic review. International Journal of Impotence Research 2023;36(4):348-354 · PMID 37697053